Mesothelioma lawyer assistance for financial recovery

New ONCONASE® Non-Small Cell Lung Cancer Data Presented at ASTRO Annual Meeting

BLOOMFIELD, N.J., Wednesday October 19th, 2005 Alfacell Corporation (Nasdaq: ACEL) today announced that Intae Lee, Ph.D., Department of Radiology, University of Pennsylvania, is presenting new data on the effectiveness of ONCONASE® (ranpirnase) against non-small cell lung cancer (NSCLC) at the 47th Annual Meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO), held on October 16-20 in Denver. Dr. Lee's presentation is entitled, "The Enhanced Efficacy Of Cisplatin And Carboplatin By The RNase ONCONASE® On A549 Human Lung Cancer Xenografts Of Nude Mice."

"In these studies, we observed several events, including whether apoptosis (programmed cell death) was induced by ONCONASE; whether ONCONASE could sensitize the efficacy of chemotherapeutic agents cisplatin and carboplatin, and the changes in tumor volume after treatments with ONCONASE in combination with either cisplatin or carboplatin," stated Dr. Lee. "The data from our research indicates that ONCONASE alone inhibited the tumor growth of A549 human NSCLC cells, and induced apoptosis of those cells. ONCONASE also enhanced the cytotoxic effects of cisplatin and carboplatin when both drugs were simultaneously administered and when cisplatin or carboplatin was added after ONCONASE, and increased the cisplatin-induced tumor growth delay. Finally, and importantly, for the treatment of large-size tumors previously treated unsuccessfully with various drugs, ONCONASE effectively showed the inhibition of tumor growth, while cisplatin and carboplatin did not show such tumoricidal effects."

Dr. Lee concluded, "These results continue to illustrate the remarkable effect of ONCONASE against NSCLC."

"Dr. Lee's elegant work builds on a significant number of studies that show ONCONASE enhances standard chemotherapeutic drugs ? even in the presence of drug resistance," stated Dr. Susanna Rybak, newest member of Alfacell's Scientific Advisory Board and former head of a laboratory at the National Cancer Institute (NCI) that helped develop the groundwork for RNase-based therapeutics. "One explanation may be found from Dr. Lee's previous observation that ONCONASE lowers tumor interstitial fluid pressure, one of the major causes of inadequate drug delivery into solid tumors."

"These studies offer further validation of ONCONASE's potential as a novel and promising cytotoxic agent," stated Kuslima Shogen, Chief Executive Officer of Alfacell. "We will continue in our collaboration with Dr. Lee and the University of Pennsylvania to build a strong compendium of data that shows ONCONASE to have significant clinical utility in the treatment of NSCLC and other solid tumors."

About Alfacell

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com.

About Non-Small Cell Lung Cancer (NSCLC)

According to the American Cancer Society, lung cancer is the leading cause of cancer deaths worldwide among men and women. NSCLC is the most common form of lung cancer, accounting for 80 percent of all lung cancer cases. In 2004, NSCLC accounted for approximately 160,000 deaths in the United States. According to industry analysts, the NSCLC drug market is projected to exceed $4 billion by 2012.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

For further information, please contact Kuslima Shogen CEO of Alfacell Corporation, +1-973-748-8082, info@alfacell.com; or financial inquiries, Stephanie Noiseux at Elite Financial Communications , +1-407-585-1080,acel@efcg.net, for Alfacell Corporation.

Alfacell Receives First-Ever Pioneer Award for Mesothelioma Research from Mesothelioma Applied Research Foundation

BLOOMFIELD, N.J., Tuesday October 11th, 2005 Alfacell Corporation (Nasdaq: ACEL) today announced that the Company was presented with a "Pioneer Award" from the Mesothelioma Applied Research Foundation (MARF) at its Second International Symposium on Malignant Mesothelioma, held last week in Las Vegas. The Pioneer Award was introduced by MARF this year to honor companies that have made substantial contributions to the field of mesothelioma research.

"It is a great honor to receive one of the first MARF Pioneer Awards," stated Kuslima Shogen, Chief Executive Officer of Alfacell, who accepted the award on behalf of the Company. "Even greater was the opportunity to meet many patients and others who have lost loved ones to mesothelioma. It was humbling to receive their praise, and inspiring to witness their grace and determination to conquer this terrible disease." Shogen concluded, "MARF has done exceptional work in drawing much-needed attention to malignant mesothelioma, an insidious cancer that affects thousands around the world. Through the annual symposium, MARF also provides a unique, interdisciplinary forum for discussion of the scientific and clinical advances in the treatment of this disease. We salute MARF for their efforts, and will continue to work with them on the mission to find a cure."

In addition to Alfacell, other inaugural Pioneer Award recipients included Eli Lilly, Merck, Biogen Idec and Fujirebio Diagnostics.

For more information about MARF, a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease, visit www.marf.org.

About Alfacell

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com.

For further information, please contact Kuslima Shogen CEO of Alfacell Corporation, +1-973-748-8082, info@alfacell.com; or financial inquiries, Stephanie Noiseux at Elite Financial Communications , +1-407-585-1080,acel@efcg.net, for Alfacell Corporation.

Alfacell to Present at Second International Symposium on Malignant Mesothelioma

BLOOMFIELD, N.J., Tuesday October 4th, 2005 --Alfacell Corporation (Nasdaq: ACEL) today announced that the Company will present at the Second International Symposium on Malignant Mesothelioma, to be held in Las Vegas from October 6-8, 2005.

The presentation, entitled, "Two ONCONASE® Clinical Trials in MM Patients Evaluated Using the EORTC Prognostic Model," will analyze whether there is a difference in survival between ONCONASE study patients categorized as 'Good' or 'Poor' risk for survival, using European Organization for the Research and Treatment of Cancer (EORTC) prognostic scores. The EORTC model was recently validated in a study from St. Bartholomew's Hospital (Lung Cancer and Mesothelioma Unit, Medical Oncology) and The London Lung Cancer Group - both based in London, UK - published in the Journal of Clinical Oncology (Volume 23:1, January 1, 2005).

Alfacell, along with companies such as Eli Lilly, Merck and Fujirebio Diagnostics, has provided an educational grant in support of the symposium, which is organized by the Mesothelioma Applied Research Foundation (MARF), a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease. For more information on the symposium or MARF, visit www.marf.org

About Alfacell

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in a confirmatory Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). According to industry data, the estimated global market for MM is $300 million, while the NSCLC market is expected to exceed $4 billion by 2012. For more information, please visit www.alfacell.com.

For further information, please contact Kuslima Shogen CEO of Alfacell Corporation, +1-973-748-8082, info@alfacell.com; or financial inquiries, Stephanie Noiseux at Elite Financial Communications , +1-407-585-1080,acel@efcg.net, for Alfacell Corporation.